Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease
BOSTON, June 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
News
Cerevance Announces Presentation at the XVI European Meeting on Glial Cells in Health and Disease
BOSTON, June 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Former Awardee and Artelo Employee, Professor Saoirse O’Sullivan will Present the 2023 Recipient with the…
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival…
Intelligent Bio Solutions Receives Guidance from U.S. FDA on a Regulatory Pathway for Expansion into the United States for its Intelligent Fingerprinting Drug Screening Cartridge
Company intends to submit 510(k) pre-market notification to the FDA NEW YORK, June 28, 2023…
Intelligent Bio Solutions Receives Guidance from U.S. FDA on a Regulatory Pathway for Expansion into the United States for its Intelligent Fingerprinting Drug Screening Cartridge
Company intends to submit 510(k) pre-market notification to the FDA NEW YORK, June 28, 2023…
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage…
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage…
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes…
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes…
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics…
Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q),…
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
Company views that results of comprehensive data analysis of TSHA-120 and development of disease progression…